Clone 44

Manufactured by BD

Sourced in Switzerland, Germany

The Clone 44 is a compact and versatile laboratory equipment designed for a range of applications. It features a temperature-controlled incubation chamber and precise temperature control functionality. The Clone 44 is intended for use in various laboratory settings, where consistent and reliable temperature conditions are required for experimentation or sample processing.

Automatically generated - may contain errors

Lab products found in correlation

Clone a16 4, by BD (2 mentions) Optiview dab detection kit, by Roche (1 mentions) Clone epr3947, by Roche (1 mentions) Clone m1, by Roche (1 mentions) Clone g219 1129, by Roche (1 mentions) Clone g168 728, by BD (1 mentions) Eber probe, by Leica (1 mentions) Clone g168 15, by BD (1 mentions) Bondmax detection system, by Leica (1 mentions) Zytodot 2c spec met cen7 probe, by ZytoVision (1 mentions) Zytodot 2c cish implementation kit, by ZytoVision (1 mentions) Clone mrq28, by Cell Marque (1 mentions) Horseradish peroxidase conjugated secondary antibody, by GE Healthcare (1 mentions) Ecl detection reagent, by GE Healthcare (1 mentions) E p1932y, by Abcam (1 mentions)

Spelling variants of this product

MSH6 (clone 44, (3 citations) MSH6 (clone 44/MSH6; (2 citations) Anti-STIM1 antibody clone 44 (2 citations) Anti-ALDH1 antibody (clone 44, (2 citations) Anti-ALDH1 mouse monoclonal antibody (clone: 44/ALDH, (2 citations) Clone Gok/44 (1 citations)

5 protocols using clone 44

Immunohistochemical Detection of DNA Mismatch Repair Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry for MSH2 (clone 25D12, Novocastra (Biosystems Switzerland, Muttenz, Switzerland), dilution 1 : 100; or Clone G219-1129, Roche Ventana Medical Systems, ready-to-use), MSH-6 (clone 44, Becton Dickinson, Allschwil, Switzerland, dilution 1 : 500; or Clone EP49, Epitomics (LabForce, Nunningen, Switzerland), dilution 1 : 50), MLH1 (clone G168-15, Becton Dickinson, dilution 1 : 100; or clone M1, Roche Ventana Medical Systems, ready-to-use) and PMS2 (clone A16-4, Becton Dickinson, dilution 1 : 300; or Clone EPR3947, Roche Ventana Medical Systems, ready-to-use) was performed using the Ventana Benchmark system or using the OptiView DAB Detection Kit (Ventana Medical Systems) followed by counterstaining with haematoxylin.
Any nuclear staining in the tumour cells was considered as ‘positive'. Complete absence of immunoreactivity in the presence of a positive internal control (lymphocytes) was scored as ‘negative'.

Feilchenfeldt J., Varga Z., Siano M., Grabsch H.I., Held U., Schuknecht B., Trip A., Hamaguchi T., Gut P., Balague O., Khanfir K., Diebold J., Jochum W., Shoji H., Kushima R., Wagner D., Shimada Y., Cats A., Knuth A., Moch H., Aebi S, & Hofer S. (2015). Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 113(5), 716-721.

+ Open protocol

+ Expand

Immunohistochemical Analysis of MMR Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemical staining for Mlh1, Msh2, Msh6 and Pms2 proteins was performed in lymphoma cells from the single Msh2^wt mouse that displayed an MSI lymphoma following Aza treatment. Briefly, 4 μm sections were incubated with monoclonal antibodies against MLH1 (1/20 dilution, clone G168–728, Pharmingen, San Diego, CA), MSH2 (1/25 dilution, clone FE11, Calbiochem, Oncogene Research Products, Cambridge, MA), MSH6 (1/25 dilution, clone 44, Becton Dickinson, Lexington, NC) and PMS2 (1/20 dilution, clone A16–4, BD PharMingen, Le Pont de Claix, France).

Bodo S., Svrcek M., Sourrouille I., Cuillières-Dartigues P., Ledent T., Dumont S., Dinard L., Lafitte P., Capel C., Collura A., Buhard O., Wanherdrick K., Chalastanis A., Penard-Lacronique V., Fabiani B., Fléjou J.F., Brousse N., Beaugerie L., Duval A, & Muleris M. (2015). Azathioprine induction of tumors with microsatellite instability: Risk evaluation using a mouse model. Oncotarget, 6(28), 24969-24977.

+ Open protocol

+ Expand

Comprehensive Tumor Biomarker Profiling

Cited 5 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The HER2-and MET-status was assessed as previously described [11] (link), [12] (link), [16] (link), [17] (link), [18] (link) using immunohistochemistry [anti-Her2/neu antibody; clone SP3, Thermo Fisher Scientific; Fremont; USA (#MA5-14509); anti-MET antibody; clone SP44; Spring Bioscience; Pleasanton, California, USA (#M3444)] and in situ–hybridization [ZytoDot 2C SPEC HER2/CEN17 Probe (#C-3032-400), ZytoDot 2C SPEC MET/CEN7 Probe (#C-3057-400) and the ZytoDot 2C CISH Implementation Kit (#C-3044-40); ZytoVision GmbH, Bremerhaven, Germany)]. Epstein–Barr virus (EBV)–encoded RNA was detected using the EBER-probe (Novocastra, Leica Microsystems GmbH, Nussloch, Germany; #PB0589) and the BondMax-detection system according to the manufacturer's instructions (Leica Microsystems GmbH). MSI status was assessed by immunostaining using antibodies directed against MLH1 (clone G168-15, BD Biosciences, Heidelberg, Germany; #MA1-25669), PMS2 (clone MRQ-28; Cell Marque Corporation, Rocklin, USA; #288M-16-ASR), MSH2 (clone FE11; Calbiochem, Merck KGaA, Darmstadt, Germany; #MABE284), and MSH6 (clone 44, BD Biosciences; #610919) as well as by comparison of the allelic profiles of the mononucleotide repeat markers BAT-25, BAT-26, NR-21, NR-24, and NR-27 in tumor and corresponding normal tissue in cases with ambiguous immunostaining [16] (link).

Schoop H., Bregenzer A., Halske C., Behrens H.M., Krüger S., Egberts J.H, & Röcken C. (2019). Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors—Comparison Against a Therapy Naïve Cohort. Translational Oncology, 13(2), 165-176.

+ Open protocol

+ Expand

Immunohistochemical Evaluation of MMR Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunoperoxidase staining for MLH1 (1:300; clone G168-728, Cell Marque), PMS2 (1:125; clone A16-4, BD Biosciences), MSH2 (1:100; clone FE11, Calbiochem), and MSH6 (1:300; clone 44, BD Biosciences) was performed on unstained CB sections with the Leica Bond III stainer (Rankin Biomedical Corporation). MMR IPOX was interpreted as retained, lost, suboptimal, or noncontributory (Figure 1, A through E; and Figure 2, A through T). Retained staining was defined as any perceivable nuclear staining in any percentage of tumor cells. The intensity of positive staining in tumor cells was compared to the intensity of staining in internal control cells. Loss of staining was defined as complete absence of nuclear staining in all tumor cells but retained in normal cells. Suboptimal staining was defined as Questionable Staining of definitive tumor cells (designated S-QS) or focal staining of Cells that were Indefinite For Tumor (designated S-CIFT). Noncontributory (NC) staining was used to describe those cases where there was lack of staining in both internal control cells (ie, normal cells such as lymphocytes, mesothelial cells, and glandular cells) and tumor cells.

Jacobi E.M., Landon G., Broaddus R.R, & Roy-Chowdhuri S. (2021). Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy. Archives of pathology & laboratory medicine, 145(1), 46-54.

+ Open protocol

+ Expand

Western Blot Analysis of ALDH1A1 in HHL-6 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Western blot analysis was performed on the HHL-6 human hepatocyte cell line and protein lysates were separated by electrophoresis on 4% to 12% Tris-glycine gels and transferred onto a poly inylidine difluoride membrane. After being blocked with 5% non-fat milk, the membrane was incubated at 4°C overnight with two separate ALDH1A1 primary antibodies (EP1932Y, Epitomics and clone 44, BD Biosciences), both at 1:500 dilution, washed, incubated with horseradish peroxidase-conjugated secondary antibody and detected with ECL detection reagent (GE Healthcare).

Chui M.H., Wang Y., Wu R.C., Seidman J., Kurman R.J., Wang T.L, & Shih I.M. (2014). Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 28(3), 437-445.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!